Mostrar el registro sencillo del ítem

Artículo

dc.creatorRosado Sánchez, Isaaces
dc.creatorHerrero Fernández, Inéses
dc.creatorGenebat González, Migueles
dc.creatorRomero, Jorge Deles
dc.creatorRiera, Melchores
dc.creatorPodzamczer, Danieles
dc.creatorOlalla, Juliánes
dc.creatorVidal, Francesces
dc.creatorMuñoz-Fernández, Mª Angeleses
dc.creatorLeal Noval, Manueles
dc.creatorPacheco López, Yolanda Maríaes
dc.date.accessioned2018-08-20T10:40:51Z
dc.date.available2018-08-20T10:40:51Z
dc.date.issued2018-07-18
dc.identifier.citationRosado Sánchez, I., Herrero-Fernández, I., Genebat González, M., Romero, J.D., Riera, M., Podzamczer, D.,...,Pacheco López, Y.M. (2018). HIV-Infected Subjects With Poor CD4 T-Cell Recovery Despite Effective Therapy Express High Levels of OX40 and α4β7 on CD4 T-Cells Prior Therapy Initiation. Frontiers in Immunology, 9, 1673-1-1673-6.
dc.identifier.issn1664-3224es
dc.identifier.urihttps://hdl.handle.net/11441/78186
dc.description.abstractBackground HIV-infected subjects with suboptimal CD4 restoration despite suppressive combined antiretroviral treatment (cART) (immunodiscordant subjects) have been classically characterized after a variable period of time under cART. Recently, we have reported that an increased frequency of proliferating CD4 T-cells in these subjects is already present before the cART onset. The potential contribution of peripheral compensatory homeostatic proliferation (HP) is yet unknown. We aimed to analyze the expression of HP-related cellular markers on CD4 T-cells of immunodiscordant subjects before cART. Go to: Methods We analyzed the expression of OX40 and α4β7 on peripheral CD4 T-cells from immunodiscordant and control subjects (n = 21 each group) before cART initiation, and also on available follow-up samples (after 24 month of suppressive cART). Additionally, we tested the expression of these markers in an in vitro system for the study of human HP processes. Go to: Results Immunodiscordant subjects showed increased levels of OX40 and α4β7 on CD4 T-cells before cART initiation. While the cART tended to reduce these levels, immunodiscordant subjects still maintained comparatively higher levels of OX40 and α4β7 after 24 months under suppressive cART. These HP-related markers were upregulated in vitro during the human HP, especially during the fast HP. Go to: Conclusion Our results are compatible with exacerbated HP processes in immunodiscordant subjects, already before the cART onset.es
dc.description.sponsorshipFondo de Investigación Sanitaria FIS PI14/01693 PI13/0796 PI16/0503es
dc.description.sponsorshipFondos Europeos para el Desarrollo Regional (FEDER) CTS2593es
dc.description.sponsorshipJunta de Andalucía. Consejería de Economía, Innovación, Ciencia y Empleo CTS2593es
dc.description.sponsorshipAGAUR 2017SGR948es
dc.description.sponsorshipGILEAD GLD14/293es
dc.description.sponsorshipThe Spanish AIDS Research Network of Excellence RD12/0017/0029 RD16/0025/0019 RD16/0025/0006es
dc.description.sponsorshipJunta de Andalucía. Consejería de Salud y Bienestar Social C-0013-2017es
dc.formatapplication/pdfes
dc.language.isoenges
dc.publisherInternational Union of Immunological Societieses
dc.relation.ispartofFrontiers in Immunology, 9, 1673-1-1673-6.
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectImmunodiscordant response to combined antiretroviral treatmentes
dc.subjectLow CD4 recoveryes
dc.subjectHomeostatic parameterses
dc.subjectHomeostatic proliferationes
dc.subjectOX40es
dc.subjectα4β7es
dc.subjectCD4 T-cell homeostasises
dc.subjectHIVes
dc.titleHIV-Infected Subjects With Poor CD4 T-Cell Recovery Despite Effective Therapy Express High Levels of OX40 and α4β7 on CD4 T-Cells Prior Therapy Initiationes
dc.typeinfo:eu-repo/semantics/articlees
dcterms.identifierhttps://ror.org/03yxnpp24
dc.type.versioninfo:eu-repo/semantics/publishedVersiones
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses
dc.contributor.affiliationInstituto de Biomedicina de Sevilla (IBIS)es
dc.relation.projectIDFISes
dc.relation.projectIDPI14/01693es
dc.relation.projectIDPI13/0796 PI16/0503es
dc.relation.projectIDCTS2593es
dc.relation.projectID2017SGR948es
dc.relation.projectIDGLD14/293es
dc.relation.projectIDRD12/0017/0029es
dc.relation.projectIDRD16/0025/0019es
dc.relation.projectIDRD16/0025/0006es
dc.relation.projectIDC-0013-2017es
dc.relation.publisherversionhttps://doi.org/10.3389/fimmu.2018.01673es
dc.identifier.doi10.3389/fimmu.2018.01673es
idus.format.extent6 p.es
dc.journaltitleFrontiers in Immunologyes
dc.publication.volumen9es
dc.publication.initialPage1673-1es
dc.publication.endPage1673-6es

FicherosTamañoFormatoVerDescripción
HIV-Infected Subjects With Poor ...1.213MbIcon   [PDF] Ver/Abrir  

Este registro aparece en las siguientes colecciones

Mostrar el registro sencillo del ítem

Attribution-NonCommercial-NoDerivatives 4.0 Internacional
Excepto si se señala otra cosa, la licencia del ítem se describe como: Attribution-NonCommercial-NoDerivatives 4.0 Internacional